Business● Low1h ago · Nov 4, 2026, 12:04 PM
BioCryst Pharmaceuticals GAAP EPS of $0.14 beats by $0.06, revenue of $180.29M beats by $14.61M
GlobeAlert Desk · curated from Seeking Alpha Tech · global
BioCryst Pharmaceuticals reported GAAP EPS of $0.14, beating estimates by $0.06, and revenue of $180.29M, exceeding estimates by $14.61M. This indicates the company performed better than expected financially.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
GlobeAlert context
What the desk knows about this story
Threat level
0 Low
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Sources
1 publisher
Single-source so far. Treat details as unconfirmed until more publishers report.
Category
Business
Not flagged as developing.
More in Business
Business24m agoMFA Financial Non-GAAP EPS of $0.26 misses by $0.04Seeking Alpha TechBusiness24m agoAmerican International Group declares $0.50 dividendSeeking Alpha TechBusiness26m agoJasper Therapeutics shares tank after announcing 1-for-30 reverse stock splitSeeking Alpha TechBusiness34m agoSharkNinja rises after Q3 earnings beat, raises full-year outlookSeeking Alpha Tech